Drug
Adoxorubicin clinical trials
Also written INNO-206 and Aldoxorubicin.
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2018 (6)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 4 |
| 2014 | 3 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 6 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 0
ImmunityBio, Inc. (17) · CytRx (1)
Often tested with
Tested in the same studies.
Nogapendekin alfa inbakicept (8) · Albumin-Bound Paclitaxel (7) · Paclitaxel (7) · Cyclophosphamide (7) · ETBX-011 (7) · GI-4000 (7) · Fluorouracil (7) · Avelumab (7)
Studies
Open first, then newest update. How each study uses adoxorubicin is read from its arms, and is right about nine times in ten.
Testing it · 18
- Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingPhase 2ImmunityBio, Inc.NCT04390399Written as Aldoxorubicin HCl
- QUILT-3.088: NANT Pancreatic Cancer VaccineWithdrawnPhase 2ImmunityBio, Inc.NCT03563144Written as Aldoxorubicin HCl
- QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung CancerWithdrawnPhase 2ImmunityBio, Inc.NCT03574649Written as Aldoxorubicin
- QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccineWithdrawnPhase 2ImmunityBio, Inc.NCT03554109Written as Aldoxorubicin HCl
- QUILT-3.080: NANT Pancreatic Cancer VaccineTerminatedPhase 1/2ImmunityBio, Inc.NCT03586869Written as Aldoxorubicin HCl
- QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.TerminatedPhase 1/2ImmunityBio, Inc.NCT03387085Written as Aldoxorubicin HCl
- QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have ProgressedTerminatedPhase 1/2ImmunityBio, Inc.NCT03387111Written as Aldoxorubicin HCl
- Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung CancerCompletedPhase 2ImmunityBio, Inc.NCT02200757Written as Aldoxorubicin
- Phase 3 Study to Treat Patients With Soft Tissue SarcomasCompletedPhase 3ImmunityBio, Inc.NCT02049905Written as Aldoxorubicin
- Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic CancerCompletedPhase 2ImmunityBio, Inc.NCT01580397Written as INNO-206
- Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With GlioblastomaCompletedPhase 2ImmunityBio, Inc.NCT02014844Written as 250 mg/m2 aldoxorubicin
- Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue SarcomaCompletedPhase 2ImmunityBio, Inc.NCT01514188Written as INNO-206
- QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedPhase 1/2ImmunityBio, Inc.NCT03387098Written as Aldoxorubicin HCl
- Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid TumorsCompletedPhase 1ImmunityBio, Inc.NCT01706835Written as aldoxorubicin
- Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid TumorsCompletedPhase 1ImmunityBio, Inc.NCT01673438Written as aldoxorubicin
- Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid TumorsCompletedPhase 1ImmunityBio, Inc.NCT02235688Written as aldoxorubicin
- Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid TumorsCompletedPhase 1ImmunityBio, Inc.NCT01337505Written as INNO-206
- INNO-206 in Patients With Small Cell Lung Cancer (SCLC)WithdrawnPhase 2CytRxNCT00472771Written as INNO-206
Codes
What other systems call adoxorubicin · ClinicalTrials.gg INT006159
- UNII (FDA) C28MV4IM0BALDOXORUBICINConfirmed FDA, NLM, Wikidata
- Wikidata Q19903239adoxorubicinConfirmed FDA, NLM, Wikidata
- DrugBank DB06013One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | C28MV4IM0B | ALDOXORUBICIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q19903239 | adoxorubicin | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB06013 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.